SCHEMBL2446356

SCHEMBL2446356

CCN(CCCc1ccccc1)/N=C(\c1ccccc1Cl)n1ccnc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.39
HTR1A P08908 2/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
ADRA1A P35348 2/20 0.39
NR1I2 O75469 2/20 0.39
NR3C1 P04150 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
OPRK1 P41145 2/20 0.39
PDE4D Q08499 2/20 0.39
CNR1 P21554 1/20 0.39
TBXA2R P21731 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
POLB P06746 2/20 0.37
SLC6A3 Q01959 2/20 0.36
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2446357 1.00 KCNH2 (0.39) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2451910 0.95 POLB (0.39) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2451913 0.95 POLB (0.39) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2451766 0.87 CNR1 (0.36) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2451764 0.87 CNR1 (0.36) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2452200 0.84 HPGD (0.36) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2452201 0.84 HPGD (0.36) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2446679 0.83 AHR (0.39) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2446681 0.83 AHR (0.39) KCNH2HTR1ASLC6A2SLC6A4ADRA1A
SCHEMBL2449642 0.83 ADRB2 (0.39) KCNH2HTR1ASLC6A2SLC6A4ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US disclosed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US disclosed
EP-2168951-A1 AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 KCNH2 850/4885HTR1A 781/4885SLC6A2 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.